Core Viewpoint - Atea Pharmaceuticals has received a notice from Bradley L. Radoff regarding his intention to nominate three director candidates for election to the Board of Directors at the upcoming 2025 Annual Meeting of Stockholders [1][2] Company Overview - Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery and development of oral antiviral therapeutics for serious viral diseases [4] - The company has developed a proprietary nucleos(t)ide prodrug platform aimed at treating single-stranded ribonucleic acid (ssRNA) viruses, which are significant causes of serious viral diseases [4] - Atea's lead program focuses on the development of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, specifically targeting Hepatitis C Virus (HCV) [4] Shareholder Engagement - The Atea Board of Directors and management maintain regular communication with shareholders and continuously evaluate strategies to enhance shareholder value [2] - The Nominating and Corporate Governance Committee will assess the director candidates in line with established practices, with formal recommendations to be included in the definitive proxy statement [2] Proxy Statement and Meeting Information - Atea plans to file a definitive proxy statement with the SEC, which will include a WHITE proxy card for the solicitation of proxies for the 2025 Annual Meeting of Stockholders [6] - The date for the 2025 Annual Meeting has not yet been scheduled, and shareholders are not required to take any action at this time [2]

Core Viewpoint - Atea Pharmaceuticals is advancing its clinical-stage antiviral drug bemnifosbuvir for the treatment of hepatitis C virus (HCV), with a Phase 3 program set to begin patient enrollment in April 2025, following positive Phase 2 results [1][4][5]. Group 1: Drug Development and Presentation - Atea presented preclinical data on bemnifosbuvir at the 38th International Conference on Antiviral Research, emphasizing the importance of cell model selection in evaluating antiviral efficacy [2][3]. - Bemnifosbuvir is being developed in combination with ruzasvir, a potent NS5A inhibitor, targeting chronic HCV infection [2][3]. Group 2: Phase 3 Program Details - The global Phase 3 program will include two open-label trials, one in the US and Canada and another outside North America, each enrolling approximately 800 treatment-naïve patients [5]. - The primary endpoint for both trials is sustained virologic response 12 weeks post-treatment (SVR12), with specific comparisons between the bemnifosbuvir/ruzavir regimen and existing treatments [6]. Group 3: Drug Efficacy and Safety - In vitro studies indicate that bemnifosbuvir is approximately 10-fold more active than sofosbuvir against various HCV strains and maintains potency against resistance-associated substitutions [7]. - Ruzasvir has shown potent antiviral activity and a favorable safety profile in clinical studies, supporting once-daily dosing [8]. Group 4: HCV Overview - HCV is a significant global health issue, with an estimated 50 million people chronically infected worldwide and approximately 242,000 deaths annually [9]. - In the US, between 2.4 and 4 million people are estimated to have HCV, with a predominance in the 20-49 age group and less than 10% having cirrhosis [9]. Group 5: Company Background - Atea Pharmaceuticals focuses on developing oral antiviral therapies for serious viral infections, leveraging its expertise in antiviral drug development and nucleos(t)ide chemistry [10].

Atea Pharmaceuticals (AVIR) Q4 2024 Earnings Call March 07, 2025 12:15 AM ET Company Participants Jonae Barnes - Senior Vice President of Investor Relations & Corporate CommunicationsJean-Pierre Sommadossi - Founder, Chairman, CEO & PresidentJanet Hammond - Chief Development OfficerArantxa Horga - Chief Medical OfficerAndrea Corcoran - CFO, Executive VP of Legal & Secretary Conference Call Participants Isabella Camaj - Equity Research AnalystAndy Hsieh - Research Analyst Operator Good afternoon, everybody, ...

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2024 Earnings Conference Call March 6, 2025 4:30 PM ET Company Participants Jonae Barnes - Senior Vice President, Investor Relations & Corporate Communications Jean-Pierre Sommadossi - Chief Executive Officer & Founder Janet Hammond - Chief Development Officer Arantxa Horga - Chief Medical Officer Andrea Corcoran - Chief Financial Officer & Executive Vice President, Legal Conference Call Participants Bella Camaj - JPMorgan Andy Hsieh - William Blair Operator Good ...

FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the fiscal year ended December 31, 2024 Washington, D.C. 20549 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39661 ATEA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its Charter) Delaware 46-0574869 (State or other jurisdict ...

Q4 and Full Year 2024 Financial and Business Update March 6, 2025 DISCLAIMERS Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results and other future ...

Financial Status - Atea Pharmaceuticals, Inc. announced preliminary unaudited cash, cash equivalents, and marketable securities balance as of December 31, 2024[4] - The financial closing procedures for Q4 and full year 2024 are not yet complete, indicating that actual results may vary from the preliminary information[6] - The estimated preliminary financial information has not been audited or reviewed by the independent registered public accounting firm[6]

Core Insights - Atea Pharmaceuticals has successfully completed an End-of-Phase 2 meeting with the FDA and is set to begin patient enrollment for its global Phase 3 program for Hepatitis C Virus (HCV) in April 2025 [1][4][3] - The company aims to evaluate the efficacy of its regimen consisting of bemnifosbuvir and ruzasvir, which has shown promising results in previous trials [3][5] - Atea's strategic initiatives include exploring partnerships to enhance shareholder value and implementing cost-cutting measures to improve operational efficiency [3][12] Company Updates - Atea reported a significant reduction in cash reserves, with cash, cash equivalents, and marketable securities totaling $454.7 million as of December 31, 2024, down from $578.1 million a year earlier [14][23] - Research and development expenses for the fourth quarter and full year 2024 were $25.7 million and $144.1 million, respectively, compared to $35.0 million and $114.2 million in 2023, indicating a strategic shift in spending [15] - The company has appointed Arthur S. Kirsch to its Board of Directors, bringing extensive experience in investment banking and strategic advisory [13] Clinical Development - The Phase 2 study of bemnifosbuvir and ruzasvir met its primary endpoints, achieving a 98% sustained virologic response (SVR12) rate in treatment-adherent patients after eight weeks [8][9] - Atea plans to conduct two open-label Phase 3 trials, one in the US and Canada and another outside North America, each enrolling approximately 800 treatment-naïve patients [5][6] - The primary endpoint for the Phase 3 trials will be SVR12, measured 12 weeks post-treatment, ensuring consistency across patient evaluations [6] Market Context - The global HCV market is estimated to be approximately $3 billion in annual net sales, with around 50 million people living with untreated HCV globally, including up to 4 million in the US [3][26] - Chronic HCV infection remains a leading cause of liver disease, with significant healthcare implications despite the availability of direct-acting antivirals [26][25]

Core Viewpoint - Atea Pharmaceuticals, Inc. is set to host a live conference call on March 6, 2025, to report its financial results for Q4 and the full year of 2024, along with a business update [1]. Company Overview - Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery and development of oral antiviral therapies for serious viral diseases [3]. - The company utilizes a proprietary nucleos(t)ide prodrug platform to develop novel product candidates targeting single-stranded RNA viruses, which are significant causes of serious viral infections [3]. - Atea's lead program focuses on the development of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, aimed at treating Hepatitis C Virus (HCV) [3]. Conference Call Details - Participants can register for the live conference call and access the audio webcast through Atea's Investor Relations website [2]. - The audio webcast will be archived on the company's website for at least 90 days following the event [2].

Core Insights - Atea Pharmaceuticals has appointed Arthur S. Kirsch to its Board of Directors, bringing extensive experience in investment banking and capital markets, particularly in the healthcare and life sciences sectors [1][2][3] Company Overview - Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing oral antiviral therapies for serious viral diseases, leveraging a proprietary nucleos(t)ide prodrug platform [5] - The company's lead program is the development of a combination treatment of bemnifosbuvir and ruzasvir for hepatitis C virus [5] Leadership Experience - Arthur S. Kirsch has over 30 years of experience in mergers and acquisitions and equity capital markets, having held senior roles at various global investment banks [2][4] - Kirsch has served as a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group since July 2019 and previously held positions at GCA Global, Vector Securities, and NatWest Securities [2][4] Strategic Importance - The addition of Kirsch to the Board is expected to strengthen Atea's strategic priorities and enhance shareholder value, particularly in exploring strategic partnerships related to its Phase 3 program [3]